Sign up to save your podcasts
Or
Share The Hill to Climb for Scaling Clinical Trials: A POV from an Industry Operator
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Hill to Climb for Scaling Clinical Trials: A POV from an Industry Operator
The ultimate goal in the Clinical Research space is to make trials more accessible to the broader population. Inevitably, the industry has been struggling with enrollment and recruitment.
In this episode, our guest Darcy Forman, Chief Delivery Officer at Science 37, shares insight into the implications of increasing clinical research accessibility, from increasing awareness among the general population to testing medications within the populations that will ultimately benefit from the treatments.
Join us as we discuss:
In this episode, our guest Darcy Forman, Chief Delivery Officer at Science 37, shares insight into the implications of increasing clinical research accessibility, from increasing awareness among the general population to testing medications within the populations that will ultimately benefit from the treatments.
Join us as we discuss:
- Pros and cons of transitioning from the pharmaceutical industry to the tech vendor/business side
- Pressing challenges of enrollment and recruitment in clinical trials
- Hurdles to providing global scalable execution
View all episodes
By Florence Healthcare
4.6
1111 ratings
The ultimate goal in the Clinical Research space is to make trials more accessible to the broader population. Inevitably, the industry has been struggling with enrollment and recruitment.
In this episode, our guest Darcy Forman, Chief Delivery Officer at Science 37, shares insight into the implications of increasing clinical research accessibility, from increasing awareness among the general population to testing medications within the populations that will ultimately benefit from the treatments.
Join us as we discuss:
In this episode, our guest Darcy Forman, Chief Delivery Officer at Science 37, shares insight into the implications of increasing clinical research accessibility, from increasing awareness among the general population to testing medications within the populations that will ultimately benefit from the treatments.
Join us as we discuss:
- Pros and cons of transitioning from the pharmaceutical industry to the tech vendor/business side
- Pressing challenges of enrollment and recruitment in clinical trials
- Hurdles to providing global scalable execution